California State Teachers Retirement System increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 63,274.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 97,723,683 shares of the biopharmaceutical company's stock after purchasing an additional 97,569,482 shares during the quarter. California State Teachers Retirement System owned approximately 94.91% of Regeneron Pharmaceuticals worth $60,934,625,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $26,000. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $26,000. Titan Wealth CI Ltd bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $29,000. Kemnay Advisory Services Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $31,000. Finally, Birchwood Financial Partners Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $32,000. 83.31% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on REGN. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. HSBC reduced their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating for the company in a research report on Monday, July 6th. BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Truist Financial upped their price target on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Fourteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $800.36.
Get Our Latest Stock Analysis on REGN
Regeneron Pharmaceuticals Price Performance
REGN stock opened at $827.72 on Monday. The stock has a market capitalization of $85.22 billion, a P/E ratio of 20.46, a P/E/G ratio of 1.62 and a beta of 0.20. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $859.34. The business has a fifty day moving average price of $738.29 and a 200-day moving average price of $719.51.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. During the same period last year, the firm posted $12.81 earnings per share. Regeneron Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.
Key Regeneron Pharmaceuticals News
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Recent commentary continues to view Regeneron as a potentially attractive long-term biotech investment, supported by its established commercial portfolio, development pipeline and strong financial profile. However, the comparison with Vertex reportedly gives Vertex the clearer near-term investment edge. Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
- Neutral Sentiment: Regeneron’s Phase 1/2 study combining cemiplimab with SNS-101 has been completed, providing a pipeline milestone, although no efficacy or regulatory results were released. Cemiplimab Combination Trial Completion
- Negative Sentiment: Several law firms are recruiting investors for a securities class action alleging that Regeneron and certain executives misled shareholders about the viability and risks of the Phase 3 Fianlimab-Libtayo trial, including its protocol change and failure to meet the primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates potential reputational, legal and financial risks. Regeneron Class Action Deadline Alert
- Negative Sentiment: Director Kathryn Guarini sold 400 shares for $340,000, while EVP Marion McCourt sold 2,346 shares for approximately $2.0 million. All sales were made under pre-arranged Rule 10b5-1 plans, reducing their value as discretionary bearish signals, but the transactions may weigh on sentiment near recent highs. SEC Insider Transaction Filing
Insider Activity at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of the business's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the sale, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 4,146 shares of company stock valued at $3,432,488. Insiders own 6.97% of the company's stock.
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Further Reading
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
